"Dextroamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
| Descriptor ID |
D003913
|
| MeSH Number(s) |
D02.092.471.683.152.110.200
|
| Concept/Terms |
Dextroamphetamine- Dextroamphetamine
- Dexamphetamine
- Dexamfetamine
- dextro-Amphetamine
- dextro Amphetamine
- d-Amphetamine
- d Amphetamine
Dextroamphetamine Sulfate- Dextroamphetamine Sulfate
- Sulfate, Dextroamphetamine
- Dextro-Amphetamine Sulfate
- Dextro Amphetamine Sulfate
- d-Amphetamine Sulfate
- d Amphetamine Sulfate
|
Below are MeSH descriptors whose meaning is more general than "Dextroamphetamine".
Below are MeSH descriptors whose meaning is more specific than "Dextroamphetamine".
This graph shows the total number of publications written about "Dextroamphetamine" by people in this website by year, and whether "Dextroamphetamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dextroamphetamine" by people in Profiles.
-
The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2015 Jun; 25(5):402-14.
-
Variability of kinematic graphomotor fluency in adults with ADHD. Hum Mov Sci. 2014 Dec; 38:331-42.
-
Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate. Postgrad Med. 2014 Sep; 126(5):31-41.
-
Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012 Jul; 73(7):977-83.
-
Visual side effects of scopolamine/ dextroamphetamine among parabolic fliers. Aviat Space Environ Med. 2011 Jul; 82(7):683-8.
-
Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Postgrad Med. 2011 May; 123(3):99-108.
-
Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Curr Med Res Opin. 2011 Jun; 27(6):1097-107.
-
Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med. 2011 Mar; 123(2):169-76.
-
Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin. 2011; 27 Suppl 2:23-33.
-
Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010 Dec; 20(6):495-502.